In recent years, Semaglutide, a drug that has achieved dual breakthroughs in blood sugar control and weight loss, has gained global popularity and become a focal point in the pharmaceutical industry. Developed by Novo Nordisk as a GLP-1 receptor agonist, it initially served as a treatment for type 2 diabetes before gaining approval for obesity management. While reshaping the therapeutic landscape for metabolic diseases, it has also been accompanied by ongoing discussions regar
R&D Journey: A Two-Decade Scientific Breakthrough
Novo Nordisk's R&D on Semaglutide began in 2004, when the team discovered that as a glucagon-like peptide-1 (GLP-1) receptor agonist, it could accurately mimic the physiological functions of the body's natural GLP-1. After over a decade of clinical trials, the drug was first approved for the treatment of type 2 diabetes in 2017. It not only effectively regulates insulin and glucagon secretion to improve blood sugar levels but also has been proven to reduce the risk of cardiovascular events, bringing multiple benefits to diabetes patients.
In 2019, the oral formulation of Semaglutide (trade name: RYBELSUS) was approved for marketing in the United States, becoming the world's first oral GLP-1 receptor agonist. This breakthrough was made possible by the R&D team's solution to a key technical challenge: adding the absorption enhancer SNAC to protect the drug from degradation by gastric enzymes, enabling direct absorption in the stomach. This significantly improved medication convenience compared to traditional injectable formulations. In June 2021, the U.S. FDA further approved its injectable formulation (trade name: Wegovy) for the treatment of adult obesity, marking the drug's official entry into the weight loss field.
Dual Efficacy: Therapeutic Value Backed by Clinical Data
The core mechanism of Semaglutide lies in activating glucagon-like peptide-1 (GLP-1) receptors, which reduces hunger by inhibiting the hypothalamic appetite center, enhances satiety by delaying gastric emptying, and regulates glucose and lipid metabolism simultaneously. This mechanism has enabled it to demonstrate remarkable efficacy in weight loss treatment: the STEP clinical trial published in the New England Journal of Medicine (NEJM) in 2021 showed that obese or overweight patients who received subcutaneous injections of 2.4mg Semaglutide weekly combined with lifestyle interventions achieved an average weight loss of 15%-18% within 68 weeks, far exceeding the effect of the placebo group.
The drug also performs exceptionally well in the treatment of diabetes. Thirty-three clinical trials involving approximately 20,000 patients have confirmed that Semaglutide can effectively lower glycated hemoglobin (HbA1c) levels, and long-term use can reduce the risk of diabetes-related complications. In January 2023, the FDA further approved it for the treatment of obesity in adolescents aged 12 and above. The STEP 3a clinical trial showed that the medication safety in the adolescent population is comparable to that in adults, with equally significant weight loss effects. As of 2023, its weight loss indication has been approved in multiple countries and regions including the United States and Europe, making it one of the mainstream drugs for obesity treatment.
Safety Debate: Risk Warnings Amidst Growing Popularity
As the global user base of Semaglutide expands, its potential side effects have gradually attracted attention. Gastrointestinal reactions are the most common. Data from the STEP clinical trial shows that 44% of users experienced nausea, 30% had diarrhea, 24% suffered from vomiting, and 20% had constipation. Most of these symptoms occur in the early stages of medication or during dosage adjustments. Medical experts suggest alleviating such reactions by starting with a low dose and gradually increasing it.
More alarming are the rare but serious risks. In 2023, the European Medicines Agency (EMA) launched an investigation following three reported cases in Iceland of suicidal ideation after using the drug. Although a direct causal relationship has not been confirmed, the U.S. FDA required a "monitor for psychiatric symptoms" warning to be added to the labels of all GLP-1 drugs in January 2024. In addition, the drug may increase the risk of pancreatitis (incidence rate: 0.3%-0.5%) and gallbladder disease (incidence rate: 1.5% in the medication group, higher than 0.8% in the placebo group), so patients with relevant medical histories should use it with caution.
The risk of thyroid C-cell tumors has also been highlighted. Animal experiments have shown that GLP-1 drugs may increase the risk of such tumors, so the drug is explicitly contraindicated for patients with a personal or family history of medullary thyroid carcinoma. At the same time, weight regain after discontinuation is a prominent issue, with data showing that approximately 67% of users regain their pre-treatment weight after stopping the medication.
Standardized Use: Experts Emphasize the Necessity of Prescription Management
Regarding the standardized use of Semaglutide, experts from the Endocrinology Branch of the Chinese Medical Association point out that the drug is suitable for people with a BMI of ≥30 (obesity) or ≥27 (overweight) who also have metabolic problems such as diabetes and hypertension, and it must be used under the guidance of a doctor.
In terms of medication guidance, the initial dose for diabetes treatment is usually 0.25mg per week, which is increased to 0.5mg after 4 weeks; for obesity treatment, a dose of 2.4mg is required directly to ensure efficacy. At the same time, users need to regularly monitor liver and kidney functions and pay attention to drug interactions when using it in combination with other drugs. For example, caution should be exercised to avoid the risk of hypoglycemia when used in combination with insulin. Novo Nordisk stated that the accumulated long-term data shows that under the premise of standardized use, the benefits of Semaglutide outweigh the potential risks.
Currently, the research and development of Semaglutide are still advancing, with improved convenience of oral formulations and expanded indications as new directions. Pharmaceutical industry analysts believe that the success of this drug has provided a new paradigm for the treatment of metabolic diseases, but balancing efficacy and safety and avoiding abuse will be a long-term challenge it faces.
